Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$145.90

-1.34 (-0.91%)

05:28
01/12/17
01/12
05:28
01/12/17
05:28

TESARO receives CRL from FDA for rolapitant IV NDA

TESARO announced that the FDA has issued a Complete Response Letter, or CRL, regarding the rolapitant IV New Drug Application, or NDA, for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. FDA requested additional information regarding the in vitro method utilized to demonstrate comparability of drug product produced at the two proposed commercial manufacturers for rolapitant IV that were included in the NDA. TESARO is working expeditiously to provide the requested information. The CRL did not identify concerns related to the safety or efficacy of rolapitant IV or request additional clinical studies. No concerns were raised regarding the active pharmaceutical ingredient, which is also used for the Varub oral product. TESARO identified potential deficiencies at the original contract manufacturer for rolapitant IV drug product, secured a second drug product supplier and included data from this manufacturer in the NDA. During the NDA review, FDA requested and TESARO provided in vitro data to demonstrate comparability of drug product made at the two manufacturing sites.

  • 30

    Jun

TSRO Tesaro
$145.90

-1.34 (-0.91%)

12/27/16
12/27/16
NO CHANGE
Target $151

Outperform
FBR Capital ups TESARO price target to $151
FBR Capital analyst Ed White raised his price target for TESARO to $151 from $133 and keeps the Outperform rating on the shares. The oncology-focused biopharmaceutical company closed Friday up $7.27 to $139.86. TESARO recently announced that the FDA has granted Priority Review for niraparib with a June 30, 2017 action date, White tells investors in a research note. He believes niraparib could be a potential blockbuster PARP inhibitor. Meanwhile, the launch of Varubi continues to "ramp up," with sequential quarter-over-quarter unit growth of 14%, the analyst writes. White says the drug achieved a 28% share of the oral NK-1 market in the U.S. in September.
01/04/17
GABE
01/04/17
NO CHANGE
GABE
Gabelli sees Incyte as more likely target following Gilead hire
Gilead (GILD) is more likely to buy Incyte (INCY) after naming Alessandro Riva to head its Hematology and Oncology Therapeutic unit, Gabelli analyst Jing He tells investors in a research note. Dr. Riva is a Novartis (NVS) veteran while Incyte is led by a team of Novartis veterans and has collaborated with Novartis Oncology on its key drug, Jakafi, the analyst points out. He believes Incyte is "big enough to move the needle" and bring long term growth to Gilead. The analyst lists Seattle Genetics (SGEN) and TESARO (TSRO) as other potential targets for the biotech giant. He believes Incyte is the "best fit."
01/09/17
LEER
01/09/17
NO CHANGE
Target $152
LEER
Outperform
TESARO price target raised to $152 from $115 at Leerink
Leerink analyst Seamus Fernandez raised his price target for TESARO to $152 from $115 to fully incorporate his high expectations for a broad label and reflect niraparib's transformation to a commercial stage asset. The analyst notes that the "strong data" from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater ovarian cancer maintenance setting, while ongoing niraparib trials in breast cancer and front-line ovarian cancer maintenance and the company's IO platform should be additional potential drivers of upside for the stock. Fernandez sees TESARO as an "attractive takeout target," and reiterates an Outperform rating on the shares.
01/10/17
LEER
01/10/17
NO CHANGE
LEER
Outperform
ARIAD acquisition supports potential takeout premium for TESARO, says Leerink
Leerink analyst Seamus Fernandez says the acquisition of ARIAD (ARIA) by Takeda (TKPYY) for $24 per share appears to be relatively in-line with other commercial stage acquisitions, and supports a potential acquisition price for TESARO (TSRO) of greater than $170 per share based on consensus forecasts. While TESARO remains well positioned to grow independently, the analyst believes a validated PARP inhibitor like niraparib could offer a durable and strategically important product opportunity for multiple suitors. He reiterates an Outperform rating on TESARO's shares.

TODAY'S FREE FLY STORIES

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$180.87

-0.99 (-0.54%)

17:47
11/22/17
11/22
17:47
11/22/17
17:47
Periodicals
Facebook tool to show users which content was Russian propaganda, says Bloomberg »

Facebook will add a tool…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$51.01

0.79 (1.57%)

17:24
11/22/17
11/22
17:24
11/22/17
17:24
Periodicals
CSX to charge more fees on customers that disregard shipping rules, Reuters says »

Starting on January 1st,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AYTU

Aytu BioScience

$3.03

0.4301 (16.54%)

17:10
11/22/17
11/22
17:10
11/22/17
17:10
Syndicate
Breaking Syndicate news story on Aytu BioScience »

Aytu BioScience files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPIX

ESSA Pharma

$0.27

0.0059 (2.27%)

17:09
11/22/17
11/22
17:09
11/22/17
17:09
Hot Stocks
ESSA Pharma to begin trading on TSX Venture Exchange »

ESSA Pharma is listing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRDN

Meridian Waste Solutions

$1.69

0.0101 (0.60%)

16:55
11/22/17
11/22
16:55
11/22/17
16:55
Syndicate
Breaking Syndicate news story on Meridian Waste Solutions »

Meridian Waste Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$161.62

-0.67 (-0.41%)

16:50
11/22/17
11/22
16:50
11/22/17
16:50
Syndicate
Breaking Syndicate news story on Air Products »

Air Products files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOT

Boot Barn

$13.49

-0.23 (-1.68%)

16:49
11/22/17
11/22
16:49
11/22/17
16:49
Syndicate
Breaking Syndicate news story on Boot Barn »

Boot Barn files $300M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$17.50

0.88 (5.29%)

, BCEI

Bonanza Creek

$32.14

0.46 (1.45%)

16:44
11/22/17
11/22
16:44
11/22/17
16:44
Hot Stocks
Icahn reports 13.51% stake in SandRidge Energy, intends to vote against Bonanza »

Icahn has read Fir Tree…

SD

SandRidge Energy

$17.50

0.88 (5.29%)

BCEI

Bonanza Creek

$32.14

0.46 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$17.50

0.88 (5.29%)

16:35
11/22/17
11/22
16:35
11/22/17
16:35
Hot Stocks
Icahn reports 13.51% stake in SandRidge Energy, intends to vote against Bonanza »

Icahn agrees with Fir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$28.43

0.32 (1.14%)

, AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

16:32
11/22/17
11/22
16:32
11/22/17
16:32
Hot Stocks
Symantec selects Amazon Web Services to deliver cloud security »

Amazon Web Services, an…

SYMC

Symantec

$28.43

0.32 (1.14%)

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

16:30
11/22/17
11/22
16:30
11/22/17
16:30
Options
Preliminary option volume of 13.6M today »

Preliminary option volume…

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

16:26
11/22/17
11/22
16:26
11/22/17
16:26
Hot Stocks
Amazon Web Services announces Amazon ML Solutions Lab program »

Amazon Web Services, Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

NRIM

Northrim BanCorp

$34.75

-0.25 (-0.71%)

16:22
11/22/17
11/22
16:22
11/22/17
16:22
Hot Stocks
Northrim BanCorp announces CFO transition »

Northrim BanCorp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

, CERN

Cerner

$70.03

3.35 (5.02%)

16:21
11/22/17
11/22
16:21
11/22/17
16:21
General news
On The Fly: Top stock stories for Wednesday »

Stocks opened in positive…

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

CERN

Cerner

$70.03

3.35 (5.02%)

HPE

HP Enterprise

$13.10

-1.02 (-7.22%)

HPQ

HP Inc.

$21.34

-1.12 (-4.99%)

DE

Deere

$145.25

6.02 (4.32%)

ROK

Rockwell Automation

$191.02

-2 (-1.04%)

EMR

Emerson

$61.88

1.53 (2.54%)

AKZOY

AkzoNobel

$31.04

0.475 (1.55%)

AXTA

Axalta Coating

$35.50

1.63 (4.81%)

GME

GameStop

$17.37

0.64 (3.83%)

GES

Guess

$15.62

-2.33 (-12.98%)

IRBT

iRobot

$68.50

-4.57 (-6.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 11

    Dec

  • 18

    Mar

CHMI

Cherry Hill Mortgage

$18.51

0.06 (0.33%)

16:21
11/22/17
11/22
16:21
11/22/17
16:21
Syndicate
Breaking Syndicate news story on Cherry Hill Mortgage »

Cherry Hill Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$49.75

-0.23 (-0.46%)

16:20
11/22/17
11/22
16:20
11/22/17
16:20
Hot Stocks
Nektar names new CRDO, CMO and CSO »

Nektar announced several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
11/22/17
11/22
16:20
11/22/17
16:20
Options
Closing CBOE SPX and VIX Index summary for November 22nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VGZ

Vista Gold

$0.68

0.0069 (1.03%)

16:18
11/22/17
11/22
16:18
11/22/17
16:18
Syndicate
Vista Gold enters $10M ATM agreement with H.C. Wainwright & Co. »

Vista Gold announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPX

GP Strategies

$23.50

-0.2 (-0.84%)

16:17
11/22/17
11/22
16:17
11/22/17
16:17
Hot Stocks
GP Strategies announces $10M share repurchase increase »

GP Strategies Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

$NSD

NASDAQ Market Internals

16:17
11/22/17
11/22
16:17
11/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPX

GP Strategies

$23.50

-0.2 (-0.84%)

16:16
11/22/17
11/22
16:16
11/22/17
16:16
Hot Stocks
GP Strategies names Michael Dugan as new CFO »

Global performance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.